Pancreatic Cancer Research

ResearcherUNSW SydneyActive in the last 2 years

Zhihong Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8445-1076; OpenAlex author ID A5100677081. Sources: OpenAlex.

Their work

Papers
20 (first author 9, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: none · 2019: none · 2020: 4 papers · 2021: 3 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 20

  1. Lipid cargo of exosomes derived from pancreatic stellate cells and cancer cells: Role in pancreatic cancer-related diabetes. Co-author DOI 10.1016/j.bbalip.2026.159736↗
  2. Pancreatic cancer cell and stellate cell-derived exosome crosstalk mediates pancreatic cancer-related diabetes. Co-author DOI 10.1016/j.pan.2026.10.015↗
  3. Proteomic profiling of small extracellular vesicles derived from mouse pancreatic cancer and stellate cells: Role in pancreatic cancer. Co-author DOI 10.1002/pmic.202300067↗
  4. Emerging role of pancreatic stellate cell-derived extracellular vesicles in pancreatic cancer. First author DOI 10.1016/j.semcancer.2023.05.007↗
  5. Small extracellular vesicles (exosomes) and their cargo in pancreatic cancer: Key roles in the hallmarks of cancer. Co-author DOI 10.1016/j.bbcan.2022.188728↗
  6. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU). Co-author DOI 10.3389/fimmu.2022.1060957↗
  7. Breaking the cycle: Targeting of NDRG1 to inhibit bi-directional oncogenic cross-talk between pancreatic cancer and stroma. Co-author DOI 10.1096/fj.202002279r↗
  8. HGF/c-Met Inhibition as Adjuvant Therapy Improves Outcomes in an Orthotopic Mouse Model of Pancreatic Cancer. First author DOI 10.3390/cancers13112763↗
  9. Role of Pancreatic Stellate Cell-Derived Exosomes in Pancreatic Cancer-Related Diabetes: A Novel Hypothesis. Co-author DOI 10.3390/cancers13205224↗
  10. Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis. Co-author DOI 10.1038/s41416-020-0782-1↗
  11. Reply letter to comments on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and el… Co-author DOI 10.1038/s41416-020-1004-6↗
  12. Targeting HGF/c-MET Axis in Pancreatic Cancer. First author DOI 10.3390/ijms21239170↗
  13. An Orthotopic Resectional Mouse Model of Pancreatic Cancer. First author DOI 10.3791/61726↗
  14. Circulating pancreatic stellate (stromal) cells in pancreatic cancer-a fertile area for novel research. First author DOI 10.1093/carcin/bgx030↗
  15. Targeting the HGF/c-MET pathway: stromal remodelling in pancreatic cancer. First author DOI 10.18632/oncotarget.20822↗
  16. Key role of pancreatic stellate cells in pancreatic cancer. First author DOI 10.1016/j.canlet.2015.10.035↗
  17. Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer. First author DOI 10.1038/bjc.2015.478↗
  18. Pancreatic cancer: The microenvironment needs attention too! First author DOI 10.1016/j.pan.2015.02.013↗
  19. The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic can… Co-author DOI 10.1093/carcin/bgu122↗
  20. Pancreatic cancer and its stroma: a conspiracy theory. Co-author DOI 10.3748/wjg.v20.i32.11216↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minoti Vivek Apte · 19 shared papers, 2014–2026 · strength 2.55
  2. Jeremy S. Wilson · 16 shared papers, 2014–2026 · strength 1.93
  3. Chamini Jayamali Perera · 8 shared papers, 2020–2026 · strength 1.53
  4. David Goldstein · 12 shared papers, 2014–2022 · strength 1.13
  5. Srinivasa P. Pothula · 11 shared papers, 2014–2021 · strength 1.00
  6. Rohit Sarkar · 3 shared papers, 2023–2026 · strength 0.78
  7. Suresh T. Chari · 3 shared papers, 2021–2026 · strength 0.57
  8. S. M. Zahid Hosen · 3 shared papers, 2022–2026 · strength 0.56
  9. Tony Pang · 5 shared papers, 2017–2022 · strength 0.55
  10. Helen Barong Binang · 2 shared papers, 2026 · strength 0.52
  11. Marco Falasca · 2 shared papers, 2021–2024 · strength 0.34
  12. Lily M. Channon · 1 shared paper, 2022 · strength 0.17
  13. Marie Ranson · 1 shared paper, 2022 · strength 0.13
  14. Mohammad Ali Moni · 1 shared paper, 2022 · strength 0.13
  15. Steve Gallinger · 1 shared paper, 2022 · strength 0.13
  16. Faiyaz Notta · 1 shared paper, 2022 · strength 0.13
  17. Marina Pajic · 1 shared paper, 2021 · strength 0.12
  18. Bekesho Geleta · 1 shared paper, 2021 · strength 0.12
  19. Žaklina Kovačević · 1 shared paper, 2021 · strength 0.12
  20. Des Raymond Richardson · 1 shared paper, 2021 · strength 0.12
  21. Sumit Sahni · 1 shared paper, 2021 · strength 0.12
  22. Takashi Murakami · 1 shared paper, 2020 · strength 0.11
  23. Neil Donald Merrett · 1 shared paper, 2017 · strength 0.08
  24. Andrew Victor Biankin · 1 shared paper, 2016 · strength 0.07
  25. Mishaal B. Patel · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.